Delivery Order SPE2DB24D3015-SPE2DB26FFWWC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,933.57 to AmerisourceBergen Drug Corp for the supply of ENGERIX-B 20 MCG/ML vaccine (syringes/milliliter) under a firm fixed price arrangement. The award was made on July 10, 2025, with an ultimate completion date of July 11, 2025, and performance is to be completed at the vendor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation and represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,573.61 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes on December 15, 2025, with an ultimate completion date of December 16, 2025. This non-set-aside contract utilizes firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,697.25 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes on December 3, 2025, with completion scheduled for December 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger relationship with DLA. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,734.75 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine (20 micrograms per milliliter syringes). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.75 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes on a firm fixed-price basis. The contract, which is non-set-aside and competitively awarded, was issued on November 24, 2025, with an ultimate completion date of November 25, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,908.70 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with a completion date of September 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $14,315.65 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with performance in Conshohocken, Pennsylvania. This firm fixed price, non-set-aside contract was competitively awarded and is scheduled for completion by August 15, 2025. The award represents a single delivery order transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of ENGERIX-B 20 MCG/ML vaccine syringes, with a ceiling value of $3,644.76 and a firm fixed price structure. This is a non-set-aside award representing a competitive procurement action. The order is due for completion by November 5, 2025, with performance to be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $3,312.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with an ultimate completion date of September 8, 2025. This non-set-aside award represents a competitively awarded transaction under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical supply vendor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,920.10 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes. This firm fixed price, competitively awarded contract was issued on September 2, 2025, with a completion date of September 3, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB26FFWWCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,762.25 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine syringes, with performance in Conshohocken, Pennsylvania. This non-competitive delivery order was awarded on November 4, 2025, with an ultimate completion date of November 5, 2025, under firm fixed-price terms. The award represents a small-value transaction typical of routine pharmaceutical replenishment activities within the federal medical supply chain. This delivery order is a child contract executed under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime vendor agreement serves as the company's primary vehicle for supplying pharmaceutical products and medical commodities to support military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial portfolio of federal contracts with the DLA and competes for pharmaceutical supply needs across multiple therapeutic domains. The ENGERIX-B vaccine delivery aligns with the Defense Health Agency's broader immunization and medical supply requirements for military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 11/4/25 |